Abivax (AAVXF) Change in Receivables (2024 - 2026)

Abivax has reported Change in Receivables for 3 years, with the latest figure at -$4.1 million in Q1 2026.

• On a quarterly basis, Change in Receivables fell 79.44% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was $8.2 billion, a 67.11% increase from a year earlier, with the FY2025 full-year figure at $8.2 billion, up 67.09% from the prior year.
• Change in Receivables was -$4.1 million for Q1 2026 at Abivax, down from $8.2 billion in the prior quarter.
• The five-year high for Change in Receivables was $8.2 billion in Q4 2025, with the low at -$5.4 million in Q3 2025.
• Average Change in Receivables over 3 years is $1.5 billion, with a median of -$735466.9 recorded in 2024.
• The largest YoY upside for Change in Receivables was 67.19% in 2025 against a maximum downside of 209.07% in 2025.
• Over 3 years, Change in Receivables stood at $4.9 billion in 2024, then jumped by 67.19% to $8.2 billion in 2025, then sank by 100.05% to -$4.1 million in 2026.
• The last three Change in Receivables figures came in at -$4.1 million (Q1 2026), $8.2 billion (Q4 2025), and -$5.4 million (Q3 2025), per Business Quant data.